Anju Software Buys Clinical Trial Software Provider ClinPlus from DZS Software

Providence Equity Partners-backed Anju Software Inc. has acquired ClinPlus, a provider of products used for the performance of clinical trials. DZS Software Solutions Inc. was the seller of Bound Brook, NJ-based ClinPlus.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Anju Software, a life sciences software platform founded in 2015, has been under the Providence Equity umbrella since June of 2016.

Providence Equity, a nearly 30-year-old global asset management firm with $50 billion in assets under management across private equity and credit businesses, focuses on deals across media, communications, education and information industries. The firm believes that Anju will help accelerate the growth of ClinPlus, as part of its overall consolidation and growth strategy in which the additional resources that Anju can provide are “essential.”

“ClinPlus has a full suite of products used for the performance of clinical trials including EDC, IWRS, CTMS, eTMF, Data Management, Coding and SAS Reporting. With this complete product suite, Anju can provide full clinical trial software support from Phase 1 to Phase 4 with a scalable web platform for CROs and pharma companies,” said Kurien Jacob, CEO of Anju Software.

Financial terms of the deal, which marks Anju’s third in 2017, were not disclosed. Providence Equity suggests the latest deal will enable Anju to enter and grow in the clinical trial space after having established a dominant position in the Medical Affairs segment with its recent acquisitions of Online Business Applications (OBA) and OpenIQ.